241 related articles for article (PubMed ID: 35804860)
1. Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome.
Oliveira E; Costa ES; Ciudad J; Gaipa G; Sedek Ł; Barrena S; Szczepanski T; Buracchi C; Silvestri D; Siqueira PFR; Mello FV; Torres RC; Oliveira LMR; Fay-Neves IVC; Sonneveld E; van der Velden VHJ; Mejstrikova E; Ribera JM; Conter V; Schrappe M; van Dongen JJM; Land MGP; Orfao A;
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804860
[TBL] [Abstract][Full Text] [Related]
2. [Clinical research on clearance of leukemic cell during induction of remission therapy in children with precursor B cell acute lymphoblastic leukemia].
Yi ZG; Cui L; Gao C; Jin M; Zhang RD; Li ZG; Wu MY
Zhonghua Er Ke Za Zhi; 2011 Mar; 49(3):170-4. PubMed ID: 21575363
[TBL] [Abstract][Full Text] [Related]
3. Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells.
Kihira K; Chelakkot VS; Kainuma H; Okumura Y; Tsuboya N; Okamura S; Kurihara K; Iwamoto S; Komada Y; Hori H
Int J Hematol; 2020 Dec; 112(6):795-806. PubMed ID: 32862292
[TBL] [Abstract][Full Text] [Related]
4. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
5. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
9. B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients.
Mendonça de Pontes R; Flores-Montero J; Sanoja-Flores L; Puig N; Pessoa de Magalhães RJ; Corral-Mateos A; Salgado AB; García-Sánchez O; Pérez-Morán J; Mateos MV; Burgos L; Paiva B; Te Marvelde J; van der Velden VHJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; Durie B; van Dongen JJM; Maiolino A; Sobral da Costa E; Orfao A
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916787
[TBL] [Abstract][Full Text] [Related]
10. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.
Iwasa M; Miura Y; Fujishiro A; Fujii S; Sugino N; Yoshioka S; Yokota A; Hishita T; Hirai H; Andoh A; Ichinohe T; Maekawa T
Int J Hematol; 2017 May; 105(5):587-597. PubMed ID: 28044259
[TBL] [Abstract][Full Text] [Related]
12. A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Popov A; Henze G; Roumiantseva J; Budanov O; Belevtsev M; Verzhbitskaya T; Boyakova E; Movchan L; Tsaur G; Fadeeva M; Lagoyko S; Zharikova L; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Fechina L; Aleinikova O; Karachunskiy A
Pediatr Blood Cancer; 2023 Jun; 70(6):e30295. PubMed ID: 36975157
[TBL] [Abstract][Full Text] [Related]
13. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of IKZF1 deletions and IKZF1
Braun M; Pastorczak A; Sędek Ł; Taha J; Madzio J; Jatczak-Pawlik I; Wypyszczak K; Matysiak M; Derwich K; Lejman M; Kazanowska B; Szczepański T; Kowalczyk JR; Mlynarski W;
Hematol Oncol; 2022 Aug; 40(3):430-441. PubMed ID: 35118711
[TBL] [Abstract][Full Text] [Related]
15. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.
Cayuela JM; Baruchel A; Orange C; Madani A; Auclerc MF; Daniel MT; Schaison G; Sigaux F
Blood; 1996 Jul; 88(1):302-8. PubMed ID: 8704188
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
[TBL] [Abstract][Full Text] [Related]
17. Detection of Minimal Residual Disease in B Cell Acute Lymphoblastic Leukemia Using an Eight-Color Tube with Dried Antibody Reagents.
Bouriche L; Bernot D; Nivaggioni V; Arnoux I; Loosveld M
Cytometry B Clin Cytom; 2019 Mar; 96(2):158-163. PubMed ID: 30698327
[TBL] [Abstract][Full Text] [Related]
18. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
[TBL] [Abstract][Full Text] [Related]
19. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
Theunissen PMJ; Sedek L; De Haas V; Szczepanski T; Van Der Sluijs A; Mejstrikova E; Nováková M; Kalina T; Lecrevisse Q; Orfao A; Lankester AC; van Dongen JJM; Van Der Velden VHJ;
Br J Haematol; 2017 Jul; 178(2):257-266. PubMed ID: 28419441
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia.
Sędek Ł; Theunissen P; Sobral da Costa E; van der Sluijs-Gelling A; Mejstrikova E; Gaipa G; Sonsala A; Twardoch M; Oliveira E; Novakova M; Buracchi C; van Dongen JJM; Orfao A; van der Velden VHJ; Szczepański T;
J Immunol Methods; 2019 Dec; 475():112429. PubMed ID: 29530508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]